Elle Macpherson's Story: What 'Stage 0' Breast Cancer Means

What she said, and what she did not

In September 2024 the model Elle Macpherson gave an interview to the Australian Women's Weekly. She was promoting her memoir. She said she had been told seven years earlier that she had what she called HER2-positive, estrogen receptive intraductal carcinoma. The Guardian gave the date as February 2017. She was 60 at the time of the interview.

She said she had a lumpectomy. That is surgery to take out the lump rather than the whole breast. Her doctors then advised a mastectomy with radiation, chemotherapy, hormone therapy, and reconstruction. She said she turned that plan down. Instead she spent eight months in Arizona, following what she called a heart-led, holistic approach. She said she is now in remission.

That is her account of her own care. This page does not second-guess it. But the coverage left out the part a clinician would need. As the Guardian reported the next day, no report carried the size of the lesion or the grade of the cells. Without those, nobody outside her team can say what the diagnosis meant.

What "intraductal carcinoma" describes

The breast is built around ducts. These are the thin tubes that carry milk toward the nipple. Intraductal carcinoma means odd cells have formed inside a duct. They have not broken through the wall of that duct into nearby breast tissue. The usual name for it is ductal carcinoma in situ, or DCIS. "In situ" is Latin for "in place." Since nothing has spread, the AJCC staging system calls it stage 0.

NCI calls DCIS a noninvasive condition. It can sit alongside invasive cancer, or turn into it, and NCI says how often and how fast both vary. Some pathologists think the word carcinoma is misleading here. They would rename it ductal intraepithelial neoplasia, to match the terms used for early cervical and prostate changes.

Professor Chris Pyke is a breast cancer surgeon. He directs medical services at the Mater private hospitals in Brisbane. He told the Guardian this is often better described as a non-invasive precancer that can turn aggressive if left alone. He put the share that turns invasive over the next year at about 5%. He also said it was quite possible that taking out the lump alone was enough treatment in her case. Our page on in situ versus invasive cancer sets out the difference.

Why the numbers on the report drive the plan

DCIS is nearly always found on a mammogram rather than by feel. NCI notes that only 4,900 US women were told they had it in 1983, before screening mammograms were common. Roughly 59,080 were expected to be told so in 2025.

Size and grade matter because they change the arithmetic. NCI cites a randomized trial of women whose DCIS was removed by lumpectomy alone. Within 90 months, 13.4% went on to get invasive cancer in the same breast. Among those who had lumpectomy plus radiation, 3.9% did.

That is the trade-off a care team weighs. Radiation cuts the chance the disease comes back in that breast. There is no evidence it changes how long anyone lives. HER2 and hormone-receptor results add a second layer. They decide whether hormone-blocking or HER2-directed drugs are on the table. Our page on what HER2 status means covers that testing.

NCI also records something steadying about the group as a whole. Among women found to have DCIS and treated for it, fewer die of breast cancer than in the general population of the same age. NCI says this may reflect how mild the condition is, or the benefit of treatment, or simply that women who turn up for screening tend to be healthier.

The label itself is not always steady

Pathologists do not always agree on where odd-looking cells end and DCIS begins. In the B-Path study, 115 working US pathologists each read one breast biopsy slide. Their readings were then set against an expert consensus. They agreed most on invasive carcinoma. They agreed much less on DCIS and on atypia, the term for cells that look unusual but are not cancer.

NCI reports what that means for the wider population. An expert panel would confirm about 92.3% of US breast biopsy readings. Some 4.6% would be read as worse than they are, and 3.2% as milder. That is one plain reason to ask for a second read of the slides. Our page on getting a second opinion explains how to ask.

When to get checked

Book an appointment for any of these, even if a recent mammogram was clear:

• A lump or firm area in the breast or armpit that stays through a full menstrual cycle
• Skin over the breast that dimples, thickens, or takes on an orange-peel texture
• A nipple that pulls inward, or scaling and crusting on it
• Fluid from one nipple that appears without squeezing, above all if it is bloody
• A change in the size or outline of one breast only

If a report already says carcinoma in situ, three questions do most of the work. How large is it? What grade are the cells? What are the hormone-receptor and HER2 results?

What this does not mean

• Stage 0 is not stage IV with a smaller number in front. It is a different situation, and the treatment talk runs differently.
• One person's outcome is not evidence about a treatment choice. A single case cannot show what else might have happened.
• Nobody outside her team knows the size, grade, or margins of her lesion. The reporting never carried them, so no comparison to your own report is possible.
• The 5% figure is a group average. It says nothing about which cases those are.
• Turning down part of a plan has real consequences either way. That talk belongs with a clinician who has the pathology in hand.

Sources

• The Guardian, Elle Macpherson refused to have chemotherapy after breast cancer diagnosis (3 September 2024) — https://www.theguardian.com/society/article/2024/sep/03/elle-macpherson-refused-chemotherapy-breast-cancer-diagnosis
• The Guardian, Crucial information missing in Elle Macpherson breast cancer story, experts warn (4 September 2024) — https://www.theguardian.com/society/article/2024/sep/04/elle-macpherson-breast-cancer-treatment-australian-womens-weekly-misinformation-risk
• TODAY, Elle Macpherson reveals breast cancer diagnosis, why she rejected traditional treatment — https://www.today.com/health/breast-cancer/elle-macpherson-breast-cancer-rcna169303
• NCI PDQ, Breast Cancer Screening (Health Professional Version) — https://www.cancer.gov/types/breast/hp/breast-screening-pdq
• NCI PDQ, Breast Cancer Treatment (Health Professional Version) — https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.